Robert's Feed
Jul 2, 2014
via Breakingviews

Tax-arbitrage M&A requires a deep discount

Photo

By Robert Cyran

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.  

Tax-arbitrage M&A requires a deep discount. U.S. companies seeking to relocate by mergers in a bid to slash how much they remit to Uncle Sam were a big part of the $1.8 trillion first-half deal boom. The benefits of such ill-conceived combinations will be fleeting, though. The more so-called inversions there are, the more likely the law is to change.

Jun 13, 2014
via Breakingviews

Priceline’s OpenTable buy is costly appetizer

Photo

By Robert Cyran

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Priceline definitely didn’t pick the budget option in its own search for expansion. The online travel outfit is paying a 46 percent premium – $2.6 billion in cash – to snag OpenTable, the listed restaurant reservation site. Each helps small businesses and customers find each other. But the tariff only makes sense if Priceline can plug many more of both into OpenTable worldwide.

Jun 9, 2014
via Breakingviews

M&A shows symptoms of overheating

Photo

By Robert Cyran and Kevin Allison

The authors are Reuters Breakingviews columnists. The opinions expressed are their own.

The merger market is showing symptoms of overheating. Global deal volume is up sharply this year – up 63 percent according to Bernstein research and 71 percent by Thomson Reuters’ tally. Monday’s announcements, meanwhile, hint at toppiness.

Jun 2, 2014
via Breakingviews

Valeant urges $54 bln deal with carrot, two sticks

Photo

By Robert Cyran

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Valeant is pushing its $54 billion deal with the help of a carrot and two sticks. The pharmaceutical group raised its offer for Allergan again on Friday, on the condition that the board of its target cooperates. Meanwhile hedge fund boss Bill Ackman on Monday threatened to unseat six directors – and Valeant could yet decide to go fully hostile. But questions over Valeant’s own stock remain its biggest weakness.

May 13, 2014
via Breakingviews

AT&T deal dialing emits a shaky signal

Photo

By Robert Cyran
The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

AT&T’s deal dialing is emitting a shaky signal. First, it wanted T-Mobile US for more domestic subscribers. After regulators nixed the idea and Verizon cleaned up its wireless joint venture, AT&T pursued Vodafone for European growth. Now, amid U.S. pay-TV consolidation, DirecTV or Dish beckons at home. The rationale is questionable and suggests the broader strategy is wayward.

Apr 29, 2014
via Breakingviews

Pfizer tax arbitrage will hasten more deals

Photo

By Robert Cyran

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Pfizer’s $99 billion tax arbitrage bid will encourage copycats. The biggest charm of the U.S. drug giant’s offer for AstraZeneca of the UK lies in switching to a lower-tax domicile. The latest and largest such deal to hit the headlines raises the odds Congress will tighten rules – but not yet.

Apr 24, 2014
via Breakingviews

U.S. investors see yet another big acquirer as hip

Photo

By Robert Cyran
The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

 

U.S. investors are seeing yet another big acquirer as hip. Zimmer’s $13.4 billion deal for rival Biomet promises savings. But the maker of knee and other joint replacements and other medical devices is giving too much away for that to justify a 15 percent, or $2.3 billion, pop in its market value, before the stock slipped back slightly in Thursday morning trading. This time, enthusiastic share buyers are betting on growth.

Apr 24, 2014
via Breakingviews

U.S. investors see yet another big acquirer as hip

Photo

By Robert Cyran
The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

 

U.S. investors are seeing yet another big acquirer as hip. Zimmer’s $13.4 billion deal for rival Biomet promises savings. But the maker of knee and other joint replacements and other medical devices is giving too much away for that to justify a 15 percent, or $2.3 billion, pop in its market value, before the stock slipped back slightly in Thursday morning trading. This time, enthusiastic share buyers are betting on growth.

Apr 22, 2014
via Breakingviews

Valeant can boost its $47 bln bid for Allergan

Photo

By Robert Cyran
The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Valeant Pharmaceuticals has plenty of room to boost its bid for Allergan. The acquisition machine, working with hedge fund manager Bill Ackman, thinks it can cut at least $2.7 billion of costs from the Botox maker. At Valeant’s single-digit tax rate, that’s worth nearly $25 billion. And the potential benefits go on from there. The $47 billion deal, based on Monday’s closing price for Valeant stock, would still add up with a much bigger premium.

Apr 22, 2014
via Breakingviews

Valeant can boost its $47 bln bid for Allergan

Photo

By Robert Cyran
The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Valeant Pharmaceuticals has plenty of room to boost its bid for Allergan. The acquisition machine, working with hedge fund manager Bill Ackman, thinks it can cut at least $2.7 billion of costs from the Botox maker. At Valeant’s single-digit tax rate, that’s worth nearly $25 billion. And the potential benefits go on from there. The $47 billion deal, based on Monday’s closing price for Valeant stock, would still add up with a much bigger premium.

    • About Robert

      "Robert Cyran, U.S. tech columnist, joined Breakingviews in London in 2003 and moved four years later to New York, where he continues to cover global technology, pharmaceuticals and special situations. Robert began his career at Forbes magazine, where he assisted in the start-up of the international version of the magazine. Before working at Breakingviews he worked as a market researcher and reporter covering the pharmaceutical industry. Robert has a Masters degree in economics from Birmingham University and an undergraduate degree from George Washington University."
    • Follow Robert